Bile acid binding/intestinal cholesterol absorption

"Bile acid binding/intestinal cholesterol absorption" does **not** refer to a specific molecular target such as a receptor, enzyme, or transporter. Instead, it describes two related physiological processes involved in lipid metabolism: 1. **Bile acid binding** refers to the interaction of certain drugs (bile acid sequestrants) with bile acids in the intestine. These drugs bind bile acids and prevent their reabsorption during enterohepatic circulation. This forces the liver to use more circulating cholesterol to synthesize new bile acids, thereby lowering blood LDL-cholesterol levels. 2. **Intestinal cholesterol absorption** is mediated by several factors including micellar solubilization by bile salts and transport across enterocytes via specific proteins such as NPC1L1 and ABC transporters like ABCA1. Drugs like ezetimibe inhibit this process by blocking key transporters. Because "Bile acid binding/intestinal cholesterol absorption" is not itself a discrete molecular entity but rather describes mechanisms or drug classes targeting these processes, it should not be considered a canonical therapeutic target name under standard conventions. If you are seeking structured information on actual targets involved in these processes—such as "Niemann-Pick C1-Like 1 protein" for intestinal cholesterol uptake or "ATP-binding cassette sub-family A member 1" for efflux—you should specify those molecules directly.

Other names

Bile acid bindingIntestinal cholesterol absorptionBile acid sequestrationCholesterol absorption inhibition

Bile acid sequestrants bind bile acids in the intestine, preventing their reabsorption and promoting excretion; this leads to increased conversion of cholesterol into bile acids in the liver, lowering blood cholesterol. Cholesterol absorption inhibitors block the intestinal transporter responsible for absorbing dietary and biliary cholesterol, reducing plasma cholesterol levels.